-
GSK preps filings for BCMA-targeting multiple myeloma drug
23 Aug 2019 09:56 GMT
… patients who had failed treatment with current drug classes.
GSK is only … inhibitor such as Takeda’s Velcade (bortezomib), as well as Johnson … for a phase 3 trial of the drug – DREAMM-3 – that will …
-
Karyopharm Announces Publication of XPOVIO™ (Selinexor) Phase 2b STORM Study Results in The New England Journal of Medicine
21 Aug 2019 21:20 GMT
… KPTI), an oncology-focused pharmaceutical company, today announced that … Drug Administration (FDA) on July 3, 2019 for the treatment … later-phase clinical trials across multiple cancer indications … study in combination with Velcade® (bortezomib) and low-dose …
-
Ribon Therapeutics Strengthens Management Team with Appointment of Sudha Parasuraman, M.D., as Chief Medical Officer and Edward Stewart as Chief Business Officer
06 Aug 2019 11:37 GMT
… for leading innovative clinical trials in the Signature … in-class cancer therapy, VELCADE®. Before joining industry, Dr … clients across the biotech, pharmaceutical and medical device industries. Tad … biology to develop effective treatments for patients with …
-
Takeda Pharmaceutical Co., Ltd. (TKPHF) CEO Christophe Weber on Q1 2019 Results - Earnings Call Transcript
01 Aug 2019 04:13 GMT
Takeda Pharmaceutical Company Limited (OTCPK:TKPHF) Q1 … the United States on the FDA website, supply shortage occurred for … to where possible pursue unmet medical need in targeted patient segments … mentioned not just VELCADE but a number of other drugs that were …
-
Moffitt Research of Selinexor for Relapsed/Refractory Multiple Myeloma Facilitates Recent FDA Approval
24 Jul 2019 23:21 GMT
… .S. Food and Drug Administration (FDA) for adult patients … melphalan — all drugs used in the treatment of multiple myeloma,” … ongoing trials at Moffitt in multiple myeloma: a trial … disease was refractory to bortezomib, carfilzomib, lenalidomide, pomalidomide …
-
Genmab Announces Approval of DARZALEX® (daratumumab) in Frontline Multiple Myeloma in Japan
22 Aug 2019 05:10 GMT
… , or bortezomib and dexamethasone, for the treatment of adult … with top tier pharmaceutical and biotechnology companies. Genmab is … and conduct of clinical trials including unforeseen safety issues … ;/www.accessdata.fda.gov/drugsatfda_docs/label …
-
Genmab Announces Submission of Biologics License Application to U.S. FDA for Subcutaneous Formulation of Daratumumab
12 Jul 2019 15:43 GMT
… or bortezomib and dexamethasone, for the treatment of adult … with other leading pharmaceutical and biotechnology companies. Contact:
… conduct of clinical trials including unforeseen safety … #47;www.accessdata.fda.gov/drugsatfda_docs/label …
-
New Cancer Drugs and Diagnostics in WHO Essential 2019 Lists
10 Jul 2019 13:37 GMT
… Essential Medicines
The WHO defines essential medicines … for metastatic melanoma.
Bortezomib (Velcade, Millenneium), lenalidomide … Ingelheim Pharmaceuticals] and gefitinib [Iressa, AstraZeneca Pharmaceuticals LP … treatment of breast cancer. Alternative drugs …
-
Genmab Announces Positive Topline Results in the Phase II GRIFFIN Study of Transplant Eligible, Newly Diagnosed Patients with Multiple Myeloma Treated with Daratumumab in Combination with Lenalidomide, Bortezomib, and Dexamethasone
08 Jul 2019 19:24 GMT
… medical conference. “The data from the Phase II GRIFFIN trial … dexamethasone, or bortezomib and dexamethasone, for treatment of adults … with top tier pharmaceutical and biotechnology companies. For more … #47;www.accessdata.fda.gov/drugsatfda_docs/label …
-
New blood cancer drug approved for patients in Scotland
08 Jul 2019 17:23 GMT
… one previous treatment has been recommended by the Scottish Medicines Consortium. (SMC … to daratumumab in combination with bortezomib and dexamethasone, and benefiting from … Darzalex, along with two other drugs, Trisenox, Ibrance, said: “We welcome …
About
© 1995-2019